Author(s)

Mengxue Zhang

Corresponding Author

Mengxue Zhang

ABSTRACT

Gastric cancer is one of the highly lethal diseases in the world, which is complex and hard to treat. The main risk factors of gastric cancer are an unbalanced diet and hereditary substances, which are common in modern society. Thus, more and more researchers focus on gastric cancer to find out better methods to survive patients including extending their lifespan and enhancing life quality. Currently, immunotherapy is becoming a vital treatment method due to its safety and high efficiency. Human epidermal growth factor receptor 2 (HER2) is one of the most important targets of advanced gastric and gastroesophageal junction cancer and is involved in the pathogenesis and poor prognosis. Several monoclonal antibody drugs for treating HER2-positive breast cancer, such as Trastuzumab and Pertuzumab, may also be beneficial to patients with HER2-positive gastric cancer. This paper discussed the mechanism, problems, and the evolution of these potential monoclonal antibody drugs for gastric cancer and hope to provide a new sight in immunotherapy of gastric cancer.

KEYWORDS

gastric cancer, Molecular targeted drug, targeted points, HER2 (Human epidermal growth factor receptor 2), Trastuzumab, Pertuzumab